Duke University Health Center — One of America's Top Heart-care Institutions and Innovators — Purchases Ventripoint's AI Heart-scan Technology

May 1, 202412:05 UTC

(TheNewswire)

Toronto, Ontario – TheNewswire - May 1, 2024 -Ventripoint Diagnostics Ltd. ("Ventripoint" orthe "Company"), (TSXV:VPT); (OTC:VPTDF)is pleased to announce that Duke UniversityHealth Center has purchased its second VMS+ unit from Ventripoint ,which processes ultrasound images of the heart to generate MRI-qualitymeasurements in minutes.

Duke Health Center Arringdon, part of the DukeUniversity Health System located in Durham, North Carolina. DukeHealth, is affiliated with Duke University and is a world-classacademic and health care system.

“Tools that allow us to reduce the cost and timeneeded for reliable diagnostics can potentially save the lives ofinfants, children and adults with heart conditions,” said RichardKrasuski, M.D., director of Duke’s Adult Congenital HeartProgram.

Duke Children’s Hospital has been usingVentripoint’s VMS+ system for two years, focusing primarily onsingle ventricle paediatric patients. Now, the VMS+ will beimplemented at Duke Cardiology Arringdon and will be used in real-timeadult patient heart scans and help Duke further its study ofVentripoint’s potential.

“We are very excited to work with Duke CardiologyArringdon on our latest VMS+ system for their cardiac clinic,” saidVentripoint Interim CEO, Hugh MacNaught. “We have had great successworking with Duke for their children’s health clinic, and we aresure that the Adult Congenital Heart Disease program will alsoexperience great results.”

The VMS+ provides diagnostic and treatment procedures,resulting in scans of all four chambers of the heart at a fraction ofthe cost and time needed for cardiac MRIs. The ease of use ofVentripoint’s A.I. technology also means that patients can receivenumerous heart scans, to assist caregivers in treatment and patientmonitoring.

As part of the purchase order, Ventripoint will updateits software at Duke as the VMS+ advances its capabilities.Ventripoint’s VMS+ is now being used in hospitals in the U.S.,Europe, the UK, and Canada.

Corporate Update

In addition to the above-described sale, over the pastmonth the Company has completed and filed its audited financialstatements, initiated an off-the-market financing, hosted meetingswith its European distributor, prepared for the AEPC conference,refreshed its website and continued the development of VMS+4.0.

Conference CallDetails

The Company will hold a conferencecall to discuss this progress.

Monday May 6th, 2024 at 4.00 pm Eastern Time

For expedited access to the call, use this registrationlink:

https://dpregister.com/sreg/10023469/f8621ab066

Dial-in details will display on screen, and a calendarinvitation will be sent by email. Registration will remain openthrough to the end of the call.

Participants who prefer to speak with an operator maydial 1-844-763-8274 or +1-647-484-8814. It is recommended that youcall 10 minutes before the scheduled start time to avoid the queue.

After the call, an audio recording will be madeavailable via telephone for one month, until end of day June 3rd. Therecording can be accessed by dialing 1-855-669-9658 or +1-604-674-8052and using the access code 0892#.

A written transcript of the call will be available onVentripoint’s website shortly after its conclusion.

About Ventripoint DiagnosticsLtd.

Ventripoint is an industry leaderin the application of AI (Artificial Intelligence) toechocardiography. Ventripoint's VMS products are powered by itsproprietary Knowledge Based Reconstruction technology, which is theresult of a decade of development and provides accurate volumetriccardiac measurements equivalent to MRI. This affordable, gold-standardalternative allows cardiologists greater confidence in the managementof their patients. Providing better care to patients serves as aspringboard and basic standard for all of Ventripoint's products thatguide our future developments. In addition, VMS+ is versatile and canbe used with all ultrasound systems from any vendor supported byregulatory market approvals in the U.S., Europe, and Canada.

For further information, pleasecontact:

Jonathan Robinson

JRobinson@oakhillfinancial.ca

416-669-1001

Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.

Forward Looking Statements

This news release contains forward-looking statementsand forward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' and similarexpressions are intended to identify forward-looking information orstatements. The forward-looking statements and information are basedon certain key expectations and assumptions made by the Company.Although the Company believes that the expectations and assumptions onwhich such forward-looking statements and information are based arereasonable, undue reliance should not be placed on the forward-lookingstatements and information because the Company can give no assurancethat they will prove to be correct.

Since forward-looking statements and informationaddress future events and conditions, by their very nature theyinvolve inherent risks and uncertainties. Actual results could differmaterially from those currently anticipated due to a number of factorsand risks. Factors which could materially affect such forward-lookinginformation are described in the risk factors in the Company's mostrecent annual management's discussion and analysis that is availableon the Company's profile on SEDAR at www.sedar.com. Readers arecautioned that the foregoing list of factors is not exhaustive. Theforward-looking statements included in this news release are expresslyqualified by this cautionary statement. The forward-looking statementsand information contained in this news release are made as of the datehereof and the Company undertakes no obligation to update publicly orrevise any forward-looking statements or information, whether as aresult of new information, future events or otherwise, unless sorequired by applicable securities laws.